LAVA Therapeutics N.V. (LVTX)

Market Cap	41.80M
Revenue (ttm)	18.79M
Net Income (ttm)	-30.90M
Shares Out	26.29M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,088
Open	1.65
Previous Close	1.60
Day's Range	1.56 - 1.68
52-Week Range	1.56 - 7.38
Beta	n/a
Analysts	Buy
Price Target	15.43 (+870.44%)
Earnings Date	May 15, 2023

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: LVTX

Financial Performance

In 2021, LVTX's revenue was 5.00 million, an increase of 42.86% compared to the previous year's 3.50 million. Losses were -45.35 million, 192.4% more than in 2020.

Financial numbers in EUR

Analyst Forecast

According to 12 analysts, the average rating for LVTX stock is "Buy." The 12-month stock price forecast is $15.43, which is an increase of 870.44% from the latest price.

Price Target

$15.43

(870.44% upside)

Analyst Consensus: Buy